Clinerion Announces New Partnership with Maxer Consulting
Clinerion today announced a new partnership with Maxer Consulting. Clinerion's Patient Network Explorer will leverage Maxer's extended network of relations in the international healthcare sector to access promising business opportunities and expand Clinerion’s patient coverage into Italy, promoting and delivering clinical trials-related solutions.
The partners' joint mission is to liaise with study sites to increase patient participation in trials to its full potential by offering tools to optimize protocol design, supporting the efficient start-up of local trials, and planning and consistently hitting realistic patient recruitment targets to enable the achievement of total timeline targets.
Maxer will support commercial and non-commercial sponsors in registering their clinical trials, uploading the results of the clinical trials on the public databases (EU and US), anonymizing the clinical data, and editing relevant scientific papers.
Read the full release, here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
